Industry Symposium With ACPE CreditNot So Positive: Treating the Negative and Cognitive Symptoms of SchizophreniaSupported by Boehringer Ingelheim

Registration Options

Activity Date: 04/07/2024

Session Time and Location

The live session is complete.

Session Summary

Modulation of dopamine levels in key brain areas affected in schizophrenia has historically been achieved by using dopamine D2 receptor antagonists. Although such D2 receptor blockade may ameliorate positive symptoms of schizophrenia, it often comes at the cost of high motor side effect risk and lack of efficacy for treating the non-positive symptoms of schizophrenia. In this presentation, the speaker will bring to light the intricate neurocircuitry affecting dopaminergic neurotransmission as it relates to schizophrenia. With this understanding, potential utilization of novel agents to modulate dopamine levels without directly affecting dopamine D2 receptors will be discussed and evaluated.

Learning Objectives

Consider the impact of negative and cognitive symptoms of schizophrenia on patient quality of life when formulating an optimal treatment strategy
Reflect on the neurobiology and neurocircuitry underlying positive, negative, and cognitive symptoms and how novel treatments with targets outside of the dopamine D2 system may affect these symptoms
Incorporate treatments that potentially improve negative and cognitive symptoms in order to optimize outcomes and quality of life for patients with schizophrenia

Faculty Information

Andrew J. Cutler, MD

View biographical information

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

The bookmark/discussion system is temporarily disabled. Please check back later.

Grant Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Claim Credits

The program evaluation and CME certificate will be available on April 7, 2024.

Create a new account at nei.global/createaccount or use your existing nei.global account
Complete your evaluation at nei.global/aapp24-schz-ce
Download or print your certificate

Questions? email CustomerService@neiglobal.com or phone 888-535-5600 (Mon-Fri: 9am5pm Pacific)